JP2015533821A - 新たな膵臓ベータ細胞の生成 - Google Patents

新たな膵臓ベータ細胞の生成 Download PDF

Info

Publication number
JP2015533821A
JP2015533821A JP2015534660A JP2015534660A JP2015533821A JP 2015533821 A JP2015533821 A JP 2015533821A JP 2015534660 A JP2015534660 A JP 2015534660A JP 2015534660 A JP2015534660 A JP 2015534660A JP 2015533821 A JP2015533821 A JP 2015533821A
Authority
JP
Japan
Prior art keywords
seq
peptide
amino acid
antibody
reg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015534660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015533821A5 (enExample
Inventor
レヴェタン クラレッサ
レヴェタン クラレッサ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Claresa Levetan
Original Assignee
Claresa Levetan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/662,245 external-priority patent/US9511110B2/en
Priority claimed from US13/662,209 external-priority patent/US8911776B2/en
Priority claimed from US13/662,253 external-priority patent/US9133440B2/en
Priority claimed from US13/662,232 external-priority patent/US20140120560A1/en
Application filed by Claresa Levetan filed Critical Claresa Levetan
Publication of JP2015533821A publication Critical patent/JP2015533821A/ja
Publication of JP2015533821A5 publication Critical patent/JP2015533821A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474—Pancreatic thread protein; Reg protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2015534660A 2012-09-27 2013-09-26 新たな膵臓ベータ細胞の生成 Pending JP2015533821A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261706225P 2012-09-27 2012-09-27
US61/706,225 2012-09-27
US13/662,245 US9511110B2 (en) 2012-09-27 2012-10-26 Generation of new pancreatic beta cells
US13/662,209 US8911776B2 (en) 2012-09-27 2012-10-26 Generation of new pancreatic beta cells
US13/662,245 2012-10-26
US13/662,253 US9133440B2 (en) 2012-09-27 2012-10-26 Generation of new pancreatic beta cells
US13/662,232 US20140120560A1 (en) 2012-10-26 2012-10-26 Generation of new pancreatic beta cells
US13/662,209 2012-10-26
US13/662,232 2012-10-26
US13/662,253 2012-10-26
PCT/US2013/061947 WO2014052611A1 (en) 2012-09-27 2013-09-26 Generation of new pancreatic beta cells

Publications (2)

Publication Number Publication Date
JP2015533821A true JP2015533821A (ja) 2015-11-26
JP2015533821A5 JP2015533821A5 (enExample) 2016-11-10

Family

ID=50388965

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015534660A Pending JP2015533821A (ja) 2012-09-27 2013-09-26 新たな膵臓ベータ細胞の生成

Country Status (5)

Country Link
EP (1) EP2900691A4 (enExample)
JP (1) JP2015533821A (enExample)
AU (1) AU2013323462A1 (enExample)
CA (1) CA2886442A1 (enExample)
WO (1) WO2014052611A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104614523B (zh) * 2014-12-19 2016-09-21 成都永安制药有限公司 结核分枝杆菌tb-sa抗体酶联免疫法检测试剂盒及其制备方法
WO2017063657A1 (en) * 2015-10-14 2017-04-20 Phlogo Aps Il1ra-derived peptide antagonist
US20190142901A1 (en) * 2017-11-16 2019-05-16 Claresa Levetan Compositions and methods for treating or preventing type 1 diabetes using a biologic response modifier in combination with one or more islet or beta cell regeneration or replacement therapies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005506362A (ja) * 2001-10-16 2005-03-03 ジーエムピー エンドテーラピューティクス インコーポレイテッド 糖尿病治療のための組成物及び方法
JP2008545712A (ja) * 2005-05-25 2008-12-18 キュアーディーエム、インク． ペプチド、その誘導体並びに類似体、及びそれらを使用する方法
JP2010538017A (ja) * 2007-08-30 2010-12-09 キュアーディーエム、インク． 膵島形成促進性ペプチドおよびそのアナログを使用する組成物および方法
US20110082080A1 (en) * 2007-10-12 2011-04-07 Curedm Group Holdings, Llc Compositions and methods of using the human proislet peptide receptor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834590A (en) * 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
JP2002525126A (ja) * 1998-09-17 2002-08-13 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Ｔｒａｆ相互作用ｅｘｔ遺伝子ファミリーの新規遺伝子ｔｒｅｘ、並びにその診断及び治療への使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005506362A (ja) * 2001-10-16 2005-03-03 ジーエムピー エンドテーラピューティクス インコーポレイテッド 糖尿病治療のための組成物及び方法
JP2008545712A (ja) * 2005-05-25 2008-12-18 キュアーディーエム、インク． ペプチド、その誘導体並びに類似体、及びそれらを使用する方法
JP2010538017A (ja) * 2007-08-30 2010-12-09 キュアーディーエム、インク． 膵島形成促進性ペプチドおよびそのアナログを使用する組成物および方法
US20110082080A1 (en) * 2007-10-12 2011-04-07 Curedm Group Holdings, Llc Compositions and methods of using the human proislet peptide receptor

Also Published As

Publication number Publication date
CA2886442A1 (en) 2014-04-03
WO2014052611A1 (en) 2014-04-03
AU2013323462A1 (en) 2015-04-23
EP2900691A4 (en) 2016-04-20
EP2900691A1 (en) 2015-08-05

Similar Documents

Publication Publication Date Title
US8829158B2 (en) Peptides, derivatives and analogs thereof, and methods of using same
JP5960661B2 (ja) 膵島形成促進性ペプチドおよびそのアナログを使用する組成物および方法
US8785400B2 (en) Methods and compositions relating to islet cell neogenesis
US20050197292A1 (en) Compositions and methods for treating T-cell mediated pathological conditions
KR102442984B1 (ko) 글루카곤 수용체 길항 항체를 이용한 제 1 형 당뇨병의 치료 방법
JP2008531730A5 (enExample)
CN110536692A (zh) 用于治疗糖尿病的含有atpif1的药物组合物
CZ20023517A3 (cs) Peptid modulující trombopoetinový receptor
US8911776B2 (en) Generation of new pancreatic beta cells
US9511110B2 (en) Generation of new pancreatic beta cells
AU2013323462A1 (en) Generation of new pancreatic beta cells
US9133440B2 (en) Generation of new pancreatic beta cells
US20140120560A1 (en) Generation of new pancreatic beta cells
WO2014018931A1 (en) Methods and compositions for treating autoimmune disease
RU2795594C2 (ru) Пептитело glp-2 для введения до, в течение или после хирургического вмешательства

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160920

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170808

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180807